Nurix Therapeutics Begins Pivotal Phase 3 Trial Testing Novel Leukemia Treatment Against Key Competitor
San Francisco, Tuesday, 4 August 2026.
On August 4, 2026, Nurix Therapeutics enrolled the first patient in a Phase 3 trial evaluating its targeted protein degrader, bexobrutideg, head-to-head against Eli Lilly’s pirtobrutinib for chronic leukemia.
Registrational Trial Enrollment Begins
On August 4, 2026, Nurix Therapeutics (NASDAQ: NRIX) announced the enrollment of the first patient in its registrational Phase 3 DAYBreak CLL-306 trial [1]. The study is designed to evaluate bexobrutideg, an oral, brain-penetrant BTK degrader, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma [1]. This milestone marks a significant advancement for Nurix’s targeted protein degradation pipeline, moving the candidate into pivotal clinical testing [1]. The global study plans to enroll approximately 620 patients, who will be randomized 1:1 to receive either 600 mg of bexobrutideg daily or pirtobrutinib [1]. Dual primary endpoints include objective response rate and progression-free survival, assessed by an independent review committee to support global regulatory submissions [1].
Competitive Dynamics in CLL Treatment
The trial initiation occurs amidst heightened competition in the BTK inhibitor space, highlighted by recent data from Eli Lilly regarding pirtobrutinib [4]. On August 3, 2026, Eli Lilly announced positive Phase 3 results for pirtobrutinib combined with venetoclax and rituximab, showing a 45% reduction in the risk of disease progression or death [4]. In the context of CLL and SLL management, treatment strategies have evolved significantly from chemoimmunotherapy toward targeted therapies and cellular options [2]. Clinical decisions are increasingly driven by symptoms and genetic markers, with emerging research identifying mutations influencing prognosis and treatment selection [2]. The head-to-head comparison in the DAYBreak CLL-306 study aims to determine if BTK degradation offers superior outcomes compared to non-covalent inhibition [1].
Strategic Collaboration and Outlook
Nurix Therapeutics is collaborating with Roche on the clinical development and potential U.S. co-commercialization of bexobrutideg [1]. This partnership is viewed as a validation of the technology platform, providing resources and expertise to support the development path [3]. Successful completion of clinical development remains a future operational goal subject to regulatory and financial risks outlined in recent filings [1]. Investors and observers are advised to monitor clinical progress,中期 data releases, and clarity on commercialization分工 as key milestones [3]. The outcome of this trial could potentially redefine the treatment landscape for patients with CLL who have previously failed covalent BTK inhibitor therapy [1].